Associated tags: Sutro Biopharma, Vaccine, Infection, Genetically modified bacteria, Periodontal disease, PCV, Antigen, IPD, SAN, Pharmaceutical industry, Safety, Ageing
Locations: BOSTON, SUTRO, SAN CARLOS, CA, US, UNITED STATES, PT
Vaccination,
Public,
Advisory Committee,
Net,
Ageing,
Tolerability,
Investment,
PCV15,
PCV,
Safety,
Phase 10,
Infant,
Infection,
Trial of the century,
Conference,
Growth,
Administration,
Lonza,
Immunization,
Exercise,
Research and development,
Bank,
ACIP,
Stage 2,
Initiate,
PCV20,
G&A,
SAN,
End,
Genetically modified bacteria,
IPD,
Vaccine SAN CARLOS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
Key Points:
- “We also continue to progress our early-stage pipeline led by VAX-A1, a vaccine candidate designed to prevent Group A Strep infections.
- The aggregate gross proceeds to Vaxcyte from this offering were $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
- The March 31, 2024 amount includes the $816.5 million in net proceeds from the follow-on offering completed in February 2024.
- As of March 31, 2024, Vaxcyte had incurred $101.8 million in total capital and facility buildout expenditures that were reflected on the Company’s balance sheet as of that date.
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m.
Key Points:
- SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m.
- ET / 9:45 a.m. PT.
- A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com .
- A replay of the webcast will be available for approximately 30 days following the conference.
SAN,
Immunization,
PCV,
Serology,
Life,
Vaccine,
Safety,
Meningitis,
Genetically modified bacteria,
IPD,
Tolerability,
Infant,
Disease,
Streptococcus pneumoniae,
Fungal infection SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
Key Points:
- Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
- “Completing enrollment of the VAX-24 study with more than 800 healthy infants demonstrates yet another significant milestone in the development of our VAX-24 and VAX-31 PCV candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
- “We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in U.S. clinics today.
- “Given the significant burden of disease in young children, there remains a need for broader-spectrum vaccines like VAX-24 and VAX-31, our next-generation 31-valent PCV candidate, that are designed to provide greater protection than the current standard-of-care.”
Retrieved on:
Tuesday, February 27, 2024
Licensure,
Investment,
Growth,
Exercise,
Tolerability,
Immunization,
Host,
Trial of the century,
Ageing,
PCV20,
PCV,
P-value,
Safety,
BLA,
Success,
Phase 10,
Genetically modified bacteria,
Net,
G&A,
CMC,
SAN,
Research and development,
ID,
OPA,
Conference,
The Lancet,
Biologics license application,
Breakthrough therapy,
Advisory Committee,
PCV15,
POC,
FDA,
End,
Food,
Breakthrough,
Element,
Fireside chats,
Administration,
IPD -- Significant Progress in Establishing Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, Including Expanded Collaboration with Lonza --
Key Points:
- ET / 1:30 p.m. PT --
SAN CARLOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
- Additionally, as part of ongoing Chemistry, Manufacturing and Controls (CMC)-focused discussions, Vaxcyte received encouraging input from the FDA regarding the VAX-24 adult licensure requirements.
- The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
- Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2024, at 4:30 p.m.
Retrieved on:
Thursday, February 15, 2024
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024.
Key Points:
- SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024.
- ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.
- A live webcast of the conference call will also be available on the investor relations page of the Vaxcyte corporate website at www.vaxcyte.com .
- After the live webcast, the event will remain archived on the Vaxcyte website for 30 days.
Security (finance),
SAN,
Bank of America,
Genetically modified bacteria,
SVB Securities,
Madison Avenue,
Telephone,
Guggenheim Partners,
Exercise,
Equity capital markets,
Cantor,
Attention,
Prospectus,
BofA Securities,
Jefferies Group,
Evercore,
Sale,
Needham & Company,
State Street This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.
Key Points:
- This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.
- The aggregate gross proceeds to Vaxcyte from this offering were approximately $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
- BofA Securities, Jefferies, Leerink Partners LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint book-running managers for the offering.
- BTIG and Needham & Company acted as lead managers for the offering.
Retrieved on:
Thursday, February 1, 2024
SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m.
Key Points:
- SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m.
- ET / 7:00 a.m. PT.
- A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com .
- A replay of the webcast will be available for approximately 30 days following the conference.
Retrieved on:
Wednesday, January 31, 2024
Security (finance),
SAN,
Bank of America,
Genetically modified bacteria,
SVB Securities,
Madison Avenue,
Telephone,
Guggenheim Partners,
Exercise,
Equity capital markets,
Cantor,
Attention,
Prospectus,
BofA Securities,
Jefferies Group,
Evercore,
Sale,
Needham & Company,
State Street Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering.
Key Points:
- Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering.
- The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant.
- The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $750.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants.
- All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.
Retrieved on:
Tuesday, January 30, 2024
Security (finance),
SAN,
Bank of America,
Genetically modified bacteria,
SVB Securities,
Madison Avenue,
Telephone,
Guggenheim Partners,
Equity capital markets,
Cantor,
Attention,
Prospectus,
BofA Securities,
Jefferies Group,
Evercore,
Sale,
Needham & Company,
State Street All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.
Key Points:
- All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.
- Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants).
- The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- BofA Securities, Jefferies, Leerink Partners, Evercore ISI, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.
Ageing,
Biologics license application,
SAN,
Genetically modified bacteria,
Public,
IPD,
Safety,
Intend,
PCV,
Trial of the century,
Vaccine SAN CARLOS, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 1/2 clinical study evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 1/2 study in the third quarter of 2024.
Key Points:
- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of IPD Circulating in the U.S.
- Adult Population --
-- Company’s Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise, VAX-24 and VAX-31, Intended to Deliver the Broadest-Spectrum of Coverage Against IPD --
SAN CARLOS, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 1/2 clinical study evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.
- Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 1/2 study in the third quarter of 2024.
- “Completing the enrollment of the VAX-31 study with more than one thousand adults 50 years and older is a significant step for our PCV franchise and we look forward to announcing topline safety, tolerability and immunogenicity data in the third quarter of this year,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
